(3-chloro-4-methoxy-benzyl)-methyl-amine | 372117-85-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-chloro-4-methoxy-benzyl)-methyl-amine
• 英文别名: (3-Chlor-4-methoxy-benzyl)-methyl-amin；3-Chlor-α-methylamino-4-methoxy-toluol；1-(3-chloro-4-methoxyphenyl)-N-methylmethanamine
• CAS: 372117-85-6
• 化学式: C₉H₁₂ClNO
• 分子量: 185.653
• InChiKey: UYQLOFIATPMQGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硝基脲 、 (3-chloro-4-methoxy-benzyl)-methyl-amine 生成 N-(3-chloro-4-methoxy-benzyl)-N-methyl-urea
  参考文献：
  名称：

  New Compounds. Some Aryl and Aralkyl Ureas

  摘要：

  DOI：

  10.1021/ja01230a047
• 作为产物：
  描述：

  N-甲基-4-甲氧基苄胺 生成 (3-chloro-4-methoxy-benzyl)-methyl-amine
  参考文献：
  名称：

  New Compounds. Some Aryl and Aralkyl Ureas

  摘要：

  DOI：

  10.1021/ja01230a047

文献信息

• Cyclic compounds
  申请人：——

  公开号：US20040142930A1

  公开（公告）日：2004-07-22

  1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, 1 wherein X is ═CH— or ═N—, Y is —NH—, —NR 4 —, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R 1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R 2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R 3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R 3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

  化合物的公式（I）或其药理学上可接受的盐，其中X为═CH—或═N—，Y为—NH—，—NR4—，—S—，—O—，—CH═N—，—N═CH—，—N═N—，—CH═CH—等，R1为较低的烷氧基，氨基，含N原子的杂环环，或者由含N原子的杂环环取代的羟基（每个都可以取代），R2为较低的烷基氨基基，可以由芳基取代，较低的烷氧基，可以由芳基取代，由含N原子的芳基取代的较低的烷氧基，R3为芳基，含N原子的杂环环，较低的烷基，较低的烷氧基，环状较低的烷氧基，由含N原子的杂环环取代的羟基，或者氨基（每个都可以取代），R3和Y中的取代基可以结合形成内酯环。本发明的化合物具有优异的选择性PDE V抑制活性，因此，可用作治疗或预防因cGMP信号传导功能障碍引起的各种疾病的药物。
• [EN] QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] DERIVES DE QUINOLEINE UTILISES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE
  申请人：GLAXO GROUP LTD

  公开号：WO2004103998A1

  公开（公告）日：2004-12-02

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20 and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了化合物的新结构，其化学式为（I）或其药用盐，其中R1、R2、R19、R20和R34如规范中所述，以及制备这些化合物的方法、含有它们的配方和它们在治疗炎症性疾病中的用途。
• Quinoline derivatives as phosphodiesterase inhibitors
  申请人：Baldwin Robert Ian

  公开号：US20070142373A1

  公开（公告）日：2007-06-21

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R 1 , R 2, R 19, R 20, and R 34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了新型化合物(I)的公式或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，制备它们的过程，含有它们的配方以及它们在治疗炎症性疾病中的用途。
• Quinoline Derivatives As Phosphodiesterase Inhibitors
  申请人：Baldwin Ian Robert

  公开号：US20090312325A1

  公开（公告）日：2009-12-17

  There are provided according to the invention novel compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R19, R20, and R34 are as described in the specification, processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases.

  根据本发明提供了一种新的化合物式(I)或其药学上可接受的盐，其中R1、R2、R19、R20和R34如规范所述，以及制备它们的过程、含有它们的制剂以及它们在治疗炎症性疾病方面的用途。
• Photomediated Spirocyclization of <i>N</i>-Benzyl Propiolamide with <i>N</i>-Iodosuccinimide for Access to Azaspiro[4.5]deca-6,9-diene-3,8-dione
  作者：Man Yang、Jiawei Hua、Hao Wang、Tao Ma、Chengkou Liu、Wei He、Ning Zhu、Yujing Hu、Zheng Fang、Kai Guo

  DOI：10.1021/acs.joc.2c00579

  日期：2022.7.1

  A metal- and oxidant-free route for affording azaspiro[4.5]deca-6,9-diene-3,8-dione via photomediated iodinated spirocyclization of N-(4-methoxybenzyl) propiolamide has been developed. The reaction underwent a radical addition/ipso-cyclization/dearomatization process at room temperature and successfully constructed C–C and C–I bonds. This green and convenient approach could be generally expanded to

  已经开发了一种通过光介导的N- (4-甲氧基苄基) 丙炔酰胺的碘化螺环化来提供 azaspiro[4.5]deca-6,9-diene-3,8-dione 的无金属和氧化剂途径。该反应在室温下经历了自由基加成/同环化/脱芳构化过程，并成功构建了C-C和C-I键。这种绿色方便的方法通常可以扩展以生产一系列碘化螺环化产物，产率中等至良好。